With a small number of approved cell therapies/ ex-vivo gene therapies and with those approved therapies reaching small patient populations there is not a proven strategy for successful large-scale commercial manufacturing. This session will briefly introduce different strategies for commercial manufacturing (e.g. centralized, regionalized, point of care, outsourced). Then move into a panel discussion to hear how various companies are pursuing commercialization and gain insights into the opportunities of these strategies. As a result of this session participants will hear from industry leaders about the regulatory, supply chain, and process technology enabling different visions of future CAR-T manufacturing.